Innovative Research Center Will Explore Hereditary Cancer Genes

Kenneth Offit

Clinical geneticist Kenneth Offit is leading the Niehaus Center.

Memorial Sloan Kettering has always been a leader in the study of inherited cancer genes. Now we’re poised to take that research to the next level, thanks to the recent creation of the Robert and Kate Niehaus Center for Inherited Cancer Genomics, established with a generous $10 million gift from philanthropist Robert Niehaus and his wife, Kate. Investigators funded by the Niehaus Center are focused on discovering the inherited causes of cancer, with the ultimate goal of using that knowledge to develop new approaches for prevention as well as earlier detection and treatment.

The Niehaus Center will make use of genomic data obtained through next-generation gene sequencing, a cutting-edge technology that enables genomes to be profiled faster and in more detail than was possible even a decade ago. MSK has already been using this type of technology through our MSK-IMPACT™ test, which finds out whether patients’ tumors carry mutations that can be targeted with drugs. The Niehaus Center will extend this approach to discover new inherited genetic changes that can be used to for both prevention and treatment.

“The Niehaus Center will take cancer risk assessment and early detection at MSK to an exciting new level,” says Kenneth Offit, Chief of MSK’s Clinical Genetics Service, who is leading the new center. “It opens a powerful window into the inherited origins of a person’s cancer. By working with these patients and their families, our genetic counselors will turn that knowledge into a preventive course of action for future generations.”

The Niehaus Center will take cancer risk assessment and early detection at MSK to an exciting new level.
Kenneth Offit Clinical geneticist

The MSK-IMPACT test, which has already screened thousands of MSK patients with advanced cancers, analyzes more than 400 of the most important cancer genes. This sequencing aims to find genetic targets for new effective therapies. To get to the heart of what makes these tumors genetically unique, a sample of the patient’s normal tissue (usually from a blood sample) is also analyzed for comparison.

Taking Advantage of Genetic Discoveries

Dr. Offit and his colleagues realized that the analysis of this normal DNA provided a treasure trove of data on the genetic alterations that cancer patients carry in their germlines (the genes inherited at birth from their parents). About two decades ago, Dr. Offit discovered the most common cancer-causing mutation in the gene BRCA2 by studying families with a history of breast and ovarian cancers.

Discovery of additional mutations in cancer susceptibility genes has led MSK’s Clinical Genetics Service to recommend increased surveillance, preventive surgeries, or other interventions for people who have inherited risks for breast, ovarian, prostate, colorectal, and thyroid cancers, among others.

Discoveries of new genes may lead to the prevention of some cancers.

Research conducted by the Niehaus Center will start with the analysis of the genes that are part of MSK-IMPACT, but those findings will be only the beginning. MSK patients who choose to participate in hereditary cancer studies will provide detailed information on their family history of cancer, and in some cases family members also may have their DNA analyzed. For families with cancer that don’t carry mutations in any of the genes that are part of MSK-IMPACT, additional genomic analyses will be performed to look for mutations in the other 20,000 human genes.

Dr. Offit explains that an important part of the process will be curating, or sifting through, the genes. “To find these mutant gene sequences, we need researchers who can interpret vast amounts of genomic data and figure out which variations are clinically important,” he says. For that purpose, Dr. Offit has named computational and experimental geneticist Vijai Joseph as Niehaus Center Associate Director for Bioinformatics Analysis. Dr. Joseph will work closely with Mark Robson, Niehaus Center Associate Director for Clinical Operations; cancer geneticist Zsofia Stadler; and Michael Walsh, a pediatric geneticist in the Niehaus Center.

Back to top

Validating Findings in the Lab

Once potential new cancer-related gene mutations are found, research in cell cultures or animal models can be used to validate that they do in fact lead to cancer. The Niehaus Center will collaborate closely with MSK’s Functional Genomics Initiative, led by molecular biologist John Petrini, to evaluate what happens to cells when a mutation under investigation is inserted into them.

Recent studies by Dr. Offit, including one published this summer in the journal PLoS Genetics, have used this technique to confirm the role of gene mutations suspected to cause some cases of acute lymphoblastic leukemia, the most common blood cancer in children. The gene alterations were first found by analyzing families with a history of the disease, and then proven to be functionally significant by investigator Sabine Topka in Dr. Offit’s lab.

Research can be used to confirm the role of certain genes.

Another recent study from members of the Niehaus Center, done in collaboration with colleagues from the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and MSK’s Department of Pathology and published last month in JAMA Oncology, looked at the findings from 1,566 patients with cancer who were analyzed with MSK-IMPACT to scan more than 300 genes, including those associated with inherited cancers.

The investigators found that 198 of the patients had mutations in genes associated with hereditary cancers, but that more than half of those mutations were not currently associated with the type of cancer for which the patient was being treated. “Doing more of these kinds of studies will increase our understanding of how inherited mutations can lead to a number of different cancers,” Dr. Offit says. “They also suggest that inherited cancers may be much more common that we previously believed.”

“And unlike other studies looking for hereditary genes, where the people who contribute DNA and other medical data are anonymous, being able to link specific mutations back to individual families going forward is a vital aspect of this effort,” Dr. Offit adds. “We plan to be able to go back to these patients and their families to inform them about what we find so that they can make healthcare decisions based on that information.”

Back to top


Commenting is disabled for this blog post.

My brother was recently dx with thyroid ca and pancreatic ca. We are 14 months apart. What should I be tested for and how? He had a ct scan of abd because of intigestion. I have alot of stomach issues and im worried.

Michelina, we’re sorry to hear about your brother’s diagnosis. If you’d like to learn more about hereditary cancer and genetic counseling, you can go to…. That page includes information on scheduling an appointment with our genetic counselors, if you decide you want to make an appointment. Best wishes to you and your family.

Hi! I am a Stage 4 B Lynch Syndrome survivor. I was genetically tested when I was diagnosed at 38 with uterine cancer. I am trying to stay ahead of the cancer by Doug preventive screening ie.. Colonoscopy, urinalysis, endoscopy.
I would like to be in contact with a DR that specializes with this gene mutation. I have a 16 year old daughter that has not yet been tested but has a 50-50 chance of also carrying the gene. I want to be proactive with her versus my being reactive when I was diagnosed.
I look forward to hearing back from someone with a Dr who specializes in Lych syndrome .
Thanks in advance for your help and assistance.
Tracy Kilbride-Hamiton

Tracy, we recommend you make an appointment with our Clinical Genetics Service. They have experts in Lynch Syndrome who can provide guidance on what kind of care and monitoring you and your family members may want to consider. You can call them at 646-888-4050 or go to… for more information. Thank you for your comment.

I heard of a new clinical gene therapy research trial in which a specific drug can target individual cancer. My father has liver Mets. He is 81 years old. Can you please provide more information? Thank you. Bes Novick

Dear Bes, we’re sorry to hear about your father’s diagnosis. Memorial Sloan Kettering has a number of trials for different drugs that target specific gene mutations in individual cancers, depending on what the mutations are. If your father would like to come here for a consultation, you can call 800-525-2225 or go to for more information on making an appointment. Thank you for your comment, and best wishes to you and your family.

I recently got results that stated I had the CDH1 mutation variance of insignificance. I've spoke to a genetic specialist who insists this just means I need closer monitoring for breast cancer. My father's family of ten including his parents have all had cancer with the exception of one aunt. 8 passes away and one survived cancer. My brother just survived intestinal concern is about stomach removal being the only prevention for HDGC associated with this mutation and no one in my area knowledgeable enough to do the procedure, also all of my questions about it are treated as if considering the stomach removal is extreme and unnecessary. Am I misunderstanding what this variance/mutation means?

Dear Michelle, we’re very sorry to hear about your family history and your current situation. If you would like to consult with one of the genetic counselors at MSK, you can call 646-888-4050 to make an appointment or go to… for more information.

If you are not in the New York City area and not able to come to MSK, you may want to consider a second opinion from an expert who lives in your area. You should be able to find one at one of the National Cancer Institute-designated cancer centers. You can find a list here:

Thank you for your comment, and best wishes to you and your family.